Drug cost development of citalopram and fluoxetine following the introduction of generic substitution in Finland

International Journal of Pharmaceutical Medicine

Volumn 21, Issue 5, 2007, Pages 363-368

  Aalto Setälä, Ville ^a   Kanerva, Risto ^a   Bell, J Simon ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; GENERIC DRUG; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; DATA BASE; DEPRESSION; DRUG COST; DRUG MARKETING; DRUG SUBSTITUTION; FINLAND; HEALTH CARE COST; HUMAN; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SOCIAL INSURANCE;

EID: 34548694947     PISSN: 13649027     EISSN: 14735679     Source Type: Journal    
DOI: 10.2165/00124363-200721050-00007     Document Type: Article

References (26)

1. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21: 89-103
2. Mossialos E, Mrazek M, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. European Observatory of Health Systems and Policies. Maidenhead: Open University Press, 2004 [online]. Available from URL: http://www.euro.who.int/document/E83015.pdf [Accessed 2007 Aug 3]
3. Kennedy J, Morgan S. A cross-national study of prescription nonadherence due to cost: data from the Joint Canada-United States Survey of Health. Clin Ther 2006; 28: 1217-24
4. Kennedy J, Coyne J, Sclar D. Drug affordability and prescription noncompliance in the United States 1997-2002. Clin Ther 2004; 26: 607-14
5. Lexchin J, Grootendorst P. Effects of prescription drug user fees on drug and health service use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv 2004; 34: 101-22
6. Schafheutle EI. Removing prescription charges for patients with mental health disorders: would it improve patient outcomes in the UK. Dis Manag Health Outcomes 2006; 14: 139-45
7. Soumerai SB, McLaughlin TJ, Ross-Degnan D. Effect of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994; 331: 650-5
8. National Agency for Medicines and The Social Insurance Institution of Finland. Finnish statistics on medicines 2005 [online]. Available from URL: http://www.kela.fi/in/internet/english.nsf/NOS/140803133205MP?.opendocument [Accessed 2006 Nov 22]
9. Bell JS, Väänänen M, Ovaskainen H, et al. Providing patient care in community pharmacies: practice and research in Finland. Ann Pharmacother 2007; 41: 1039-46
10. Aalto-Setälä V. The impact of generic substitution on price competition in Finland. Eur J Health Econ 2007 May 17. Epub ahead of print
11. Social Insurance Institution of Finland. Generic substitution, the first year [online]. Available from URL: http://www.fpa.fi/in/internet/english.nsf/ NET/190504143426MP?.Open Document [Accessed 2006 Nov 6]
12. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy 2004; 68: 47-54
13. Hollis A. The anti-competitive effects of brand controlled "pseudo-generics" in the Canadian pharmaceutical market. Can Public Policy 2003; 19: 21-32
14. Probyn AJ. Some drugs more equal than others: pseudo-generics and commercial practice. Aust Health Rev 2004; 28: 207-17
15. Congressional Budget Office. How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. 1998 July. Washington, DC: US Government Printing Office, 1998 [online]. Available from URL: http://www.cbo.gov/ftpdoc.cfm?.index=655&type=0&sequence=0 [Accessed 2007 Aug 3]
16. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manage Strat 1997; 6: 75-90
17. Suh D-C, Manning WG, Schondelmeyer S, et al. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry. Health Serv Res 2000; 35: 529-47
18. National Agency for Medicines and The Social Insurance Institution of Finland. Medicine costs and their reimbursement in 1990-2005 [online]. Available from URL: http://www.kela.fi/in/internet/english.nsf/NET/220703153454MP? OpenDocument [Accessed 2007 Aug 2]
19. Sernyak MJ, Rosenheck RA. Generic fluoxetine and choice of antidepressant medication. Psychiatr Serv 2007; 58: 128-30
20. Shrank WH, Joseph GJ, Choudhry NK, et al. Physicians' perceptions of relevant prescription drug costs: do costs to the patient or to the population matter most? Am J Manag Care 2006; 12: 545-51
21. Reichert S, Simon T, Halm EA. Physicians' attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med 2000; 160: 2799-803
22. Andersson K, Sonesson C, Petzold M, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 2005; 14: 341-8
23. Guignard E, Bugnon O. Pharmaceutical care in community pharmacies: practice and research in Switzerland. Ann Pharmacother 2006; 40: 512-7
24. Kjoenniksen I, Lindbaek M, Granas AG. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006; 28: 284-9
25. Heikkilä R, Mäntyselkä P, Hartikainen-Herranen K, et al. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Policy 2007 Aug; 82 (3): 366-74
26. Heaney DC, Sander JW. Antiepileptic drugs: generic versus branded treatments. Lancet Neurol 2007; 6: 465-8